The general strategy for therapeutically targeting proteases is to identify a specific inhibitor — generally a small molecule — that blocks the active site. As discussed below, discovery ...

and proximity-ligation based assays for active proteases (using a combination of peptides that bind only to the active form of proteases and specific antibody) and protease–inhibitor complexes. Most ...